Your browser doesn't support javascript.
Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
Osowicki, Joshua; Morgan, Hannah J; Harris, Adele; Clothier, Hazel J; Buttery, Jim P; Kiers, Lynette; Crawford, Nigel W.
  • Osowicki J; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbou
  • Morgan HJ; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia; Centre for Health Analytics, Royal Children's Hospital Melbourne
  • Harris A; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Clothier HJ; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Centre for Health Analytics, Royal Children's Hospital Melbourne, Melbourne, Victoria Australia; School of Population and Global Health, University
  • Buttery JP; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbou
  • Kiers L; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Medicine, Faculty of Medicine, Health and Dentistry, University of Melbourne, Melbourne, Victoria, Australia.
  • Crawford NW; Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbou
Vaccine ; 40(52): 7579-7585, 2022 Dec 12.
Article in English | MEDLINE | ID: covidwho-2211585
ABSTRACT
Guillain-Barré syndrome (GBS) is an adverse event of special interest (AESI) for surveillance systems monitoring adverse events following immunisation (AEFI) with COVID-19 vaccines. Emerging data support a temporal association between GBS and adenovirus-vector COVID-19 vaccines. We present a case series of GBS reports submitted between February and November 2021 to our enhanced spontaneous surveillance system (SAEFVIC) in Victoria, Australia, following vaccination with either the adenovirus-vector vaccine Vaxzevria ChadOx1-S (AstraZeneca) or an mRNA vaccine (Comirnaty BNT162b2 [Pfizer-BioNTech] or Spikevax mRNA-1273 [Moderna]). For each report, Brighton Collaboration case definitions were used to describe diagnostic certainty. Severity was graded using the GBS Disability Score. The observed incidence of GBS following immunisation against COVID-19 was compared to expected background ICD10-AM G61.0 coded hospitalisations. There were 41 total cases of GBS reported to SAEFVIC following Vaxzevria (n = 38), Comirnaty (n = 3), or Spikevax (n = 0) vaccines. The observed GBS incidence rate exceeded the expected background rate for Vaxzevria only, with 1.85 reports per 100,000 doses following dose 1, higher than the expected rate of 0.39 hospital admissions per 100,000 adults within 42 days of vaccination. Of 38 GBS reports following Vaxzevria, the median age at vaccination was 66 years and median onset of symptoms was 14 days following immunisation. There was one death. Four cases initially categorised as GBS were later reclassified as acute-onset chronic inflammatory demyelinating polyneuropathy. Fatigue was the predominant persisting symptom reported at follow up. Additional global studies are required to characterise risk factors, clinical variability, and to provide precision and generalizability regarding AEFI risks such as GBS associated with different vaccine platforms, which will help inform communication of the potential benefits and risks of COVID19 vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Humans Country/Region as subject: Oceania Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Guillain-Barre Syndrome / COVID-19 Type of study: Case report / Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Humans Country/Region as subject: Oceania Language: English Journal: Vaccine Year: 2022 Document Type: Article